Diageo share price barely moves as investors wait for Feb results and CEO’s next steps
26 January 2026
1 min read

Diageo share price barely moves as investors wait for Feb results and CEO’s next steps

London, Jan 26, 2026, 09:10 GMT — Regular session

  • Diageo shares were mostly flat in early London trading, following a sluggish finish to last week
  • Investors are eyeing interim results due Feb. 25 for fresh insights on strategy and demand
  • The stock is still far from its 52-week high, adding pressure on management

Diageo edged up 0.03% to 1,675.5 pence in early Monday trading, just above last Friday’s close of 1,675.0 pence. The shares remain roughly 34% shy of their 52-week peak at 2,535 pence.

It’s crucial since Diageo’s upcoming results arrive in a market that’s lost patience with major consumer players. Investors are eager to see which changes under the new CEO are making an impact and if the demand slump has finally bottomed out.

European shares held steady, as investors stayed cautious following recent tariff concerns and ahead of this week’s U.S. Federal Reserve policy announcement.

Diageo has set expectations low for the year. In an “aide memoire” issued this month, the company reiterated its fiscal 2026 guidance for organic net sales growth — that is, like-for-like — to be flat or slightly negative. The firm pointed to challenges from Chinese white spirits and a softer U.S. consumer market than anticipated. www.diageo.com

The company has also relied on its Accelerate programme, expecting it to drive low- to mid-single-digit organic operating profit growth as cost savings come through.

Sir Dave Lewis, stepping in as CEO on Jan. 1, acknowledged the market is dealing with “some headwinds” but emphasized “significant opportunities” ahead. www.diageo.com

Since Diageo slashed its annual forecast in November, the stock has struggled to stabilize amid softer U.S. sales and a sharp drop in China caused by baijiu’s slump.

China is still a hot topic. Bloomberg reported earlier this month that Diageo is exploring options for its China assets, possibly including a sale. The company declined to comment to Reuters when asked.

Dividends and balance sheet moves could spark fresh tensions. Back in November, Fintan Ryan at Goodbody flagged asset sales as still being “part of the strategy” to lower leverage. Chris Beckett from Quilter Cheviot suggested a dividend cut might ease pressure over time, though it could weigh on shares initially. Reuters

The downside risk remains: a drawn-out U.S. slowdown, ongoing discounts in spirits, or another weak spell in China could push companies to make harder calls on pricing, spending, and returns.

Diageo’s interim results drop on Feb. 25, putting focus on whether the company will revise guidance or signal changes in capital allocation, especially dividends.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Revolution Medicines Receives FDA Nod to Review Daraxonrasib for Advanced Pancreatic Cancer
    July 23, 2026, 2:48 PM EDT. Revolution Medicines (RVMD) said the FDA has accepted its marketing submission for daraxonrasib, intended for metastatic pancreatic ductal adenocarcinoma (PDAC). The application will be evaluated as part of the CNPV pilot program for accelerated regulatory review. Results from the phase III RASolute 302 trial indicated that daraxonrasib lowered the risk of death by 60% and almost doubled median overall survival. RVMD shares have climbed 130% year to date, highlighting strong backing from investors.
Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus
Previous Story

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom
Next Story

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom